NASDAQ:KURA

Kura Oncology Competitors

$28.84
-0.63 (-2.14 %)
(As of 04/16/2021 10:55 AM ET)
Add
Compare
Today's Range
$28.43
Now: $28.84
$29.21
50-Day Range
$24.76
MA: $28.52
$31.70
52-Week Range
$9.88
Now: $28.84
$43.00
Volume4,543 shs
Average Volume740,641 shs
Market Capitalization$1.91 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.15

Competitors

Kura Oncology (NASDAQ:KURA) Vs. RARE, ARWR, GWPH, ASND, TGTX, and IONS

Should you be buying KURA stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Kura Oncology, including Ultragenyx Pharmaceutical (RARE), Arrowhead Pharmaceuticals (ARWR), GW Pharmaceuticals (GWPH), Ascendis Pharma A/S (ASND), TG Therapeutics (TGTX), and Ionis Pharmaceuticals (IONS).

Ultragenyx Pharmaceutical (NASDAQ:RARE) and Kura Oncology (NASDAQ:KURA) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, dividends, analyst recommendations, earnings, profitability and risk.

Risk and Volatility

Ultragenyx Pharmaceutical has a beta of 2.19, meaning that its stock price is 119% more volatile than the S&P 500. Comparatively, Kura Oncology has a beta of 2.15, meaning that its stock price is 115% more volatile than the S&P 500.

Insider & Institutional Ownership

94.7% of Kura Oncology shares are held by institutional investors. 8.2% of Ultragenyx Pharmaceutical shares are held by insiders. Comparatively, 11.0% of Kura Oncology shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Ultragenyx Pharmaceutical and Kura Oncology's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ultragenyx Pharmaceutical$103.71 million70.18$-402,730,000.00($7.36)-14.77
Kura OncologyN/AN/A$-63,140,000.00($1.51)-19.10

Kura Oncology has lower revenue, but higher earnings than Ultragenyx Pharmaceutical. Kura Oncology is trading at a lower price-to-earnings ratio than Ultragenyx Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Ultragenyx Pharmaceutical and Kura Oncology's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Ultragenyx Pharmaceutical-119.19%-50.69%-26.87%
Kura OncologyN/A-30.96%-28.02%

Analyst Ratings

This is a breakdown of current recommendations for Ultragenyx Pharmaceutical and Kura Oncology, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Ultragenyx Pharmaceutical06802.57
Kura Oncology011002.91

Ultragenyx Pharmaceutical presently has a consensus price target of $131.20, suggesting a potential upside of 20.73%. Kura Oncology has a consensus price target of $39.5455, suggesting a potential upside of 37.12%. Given Kura Oncology's stronger consensus rating and higher possible upside, analysts plainly believe Kura Oncology is more favorable than Ultragenyx Pharmaceutical.

Summary

Kura Oncology beats Ultragenyx Pharmaceutical on 10 of the 13 factors compared between the two stocks.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) and Kura Oncology (NASDAQ:KURA) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, dividends, analyst recommendations, earnings, profitability and risk.

Risk and Volatility

Arrowhead Pharmaceuticals has a beta of 1.62, meaning that its stock price is 62% more volatile than the S&P 500. Comparatively, Kura Oncology has a beta of 2.15, meaning that its stock price is 115% more volatile than the S&P 500.

Insider & Institutional Ownership

65.5% of Arrowhead Pharmaceuticals shares are held by institutional investors. Comparatively, 94.7% of Kura Oncology shares are held by institutional investors. 4.0% of Arrowhead Pharmaceuticals shares are held by insiders. Comparatively, 11.0% of Kura Oncology shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Arrowhead Pharmaceuticals and Kura Oncology's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Arrowhead Pharmaceuticals$87.99 million79.69$-84,550,000.00($0.84)-80.43
Kura OncologyN/AN/A$-63,140,000.00($1.51)-19.10

Kura Oncology has lower revenue, but higher earnings than Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than Kura Oncology, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Arrowhead Pharmaceuticals and Kura Oncology's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Arrowhead Pharmaceuticals-96.09%-17.37%-15.19%
Kura OncologyN/A-30.96%-28.02%

Analyst Ratings

This is a breakdown of current recommendations for Arrowhead Pharmaceuticals and Kura Oncology, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Arrowhead Pharmaceuticals021002.83
Kura Oncology011002.91

Arrowhead Pharmaceuticals presently has a consensus price target of $85.3077, suggesting a potential upside of 26.27%. Kura Oncology has a consensus price target of $39.5455, suggesting a potential upside of 37.12%. Given Kura Oncology's stronger consensus rating and higher possible upside, analysts plainly believe Kura Oncology is more favorable than Arrowhead Pharmaceuticals.

Summary

Kura Oncology beats Arrowhead Pharmaceuticals on 8 of the 12 factors compared between the two stocks.

GW Pharmaceuticals (NASDAQ:GWPH) and Kura Oncology (NASDAQ:KURA) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, dividends, analyst recommendations, earnings, profitability and risk.

Risk and Volatility

GW Pharmaceuticals has a beta of 2.15, meaning that its stock price is 115% more volatile than the S&P 500. Comparatively, Kura Oncology has a beta of 2.15, meaning that its stock price is 115% more volatile than the S&P 500.

Insider & Institutional Ownership

81.0% of GW Pharmaceuticals shares are held by institutional investors. Comparatively, 94.7% of Kura Oncology shares are held by institutional investors. 3.1% of GW Pharmaceuticals shares are held by insiders. Comparatively, 11.0% of Kura Oncology shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares GW Pharmaceuticals and Kura Oncology's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
GW Pharmaceuticals$311.33 million22.04$-9,020,000.00($0.24)-912.08
Kura OncologyN/AN/A$-63,140,000.00($1.51)-19.10

GW Pharmaceuticals has higher revenue and earnings than Kura Oncology. GW Pharmaceuticals is trading at a lower price-to-earnings ratio than Kura Oncology, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares GW Pharmaceuticals and Kura Oncology's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
GW Pharmaceuticals-11.05%-7.46%-6.13%
Kura OncologyN/A-30.96%-28.02%

Analyst Ratings

This is a breakdown of current recommendations for GW Pharmaceuticals and Kura Oncology, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
GW Pharmaceuticals010402.29
Kura Oncology011002.91

GW Pharmaceuticals presently has a consensus price target of $204.0909, suggesting a potential downside of 6.69%. Kura Oncology has a consensus price target of $39.5455, suggesting a potential upside of 37.12%. Given Kura Oncology's stronger consensus rating and higher possible upside, analysts plainly believe Kura Oncology is more favorable than GW Pharmaceuticals.

Summary

Kura Oncology beats GW Pharmaceuticals on 7 of the 12 factors compared between the two stocks.

Ascendis Pharma A/S (NASDAQ:ASND) and Kura Oncology (NASDAQ:KURA) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, dividends, analyst recommendations, earnings, profitability and risk.

Insider & Institutional Ownership

94.7% of Kura Oncology shares are held by institutional investors. 40.0% of Ascendis Pharma A/S shares are held by insiders. Comparatively, 11.0% of Kura Oncology shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Ascendis Pharma A/S and Kura Oncology's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Ascendis Pharma A/S-4,042.79%-55.72%-49.42%
Kura OncologyN/A-30.96%-28.02%

Analyst Ratings

This is a breakdown of current recommendations for Ascendis Pharma A/S and Kura Oncology, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Ascendis Pharma A/S011102.92
Kura Oncology011002.91

Ascendis Pharma A/S presently has a consensus price target of $187.6667, suggesting a potential upside of 52.69%. Kura Oncology has a consensus price target of $39.5455, suggesting a potential upside of 37.12%. Given Ascendis Pharma A/S's stronger consensus rating and higher possible upside, research analysts plainly believe Ascendis Pharma A/S is more favorable than Kura Oncology.

Risk and Volatility

Ascendis Pharma A/S has a beta of 0.77, meaning that its stock price is 23% less volatile than the S&P 500. Comparatively, Kura Oncology has a beta of 2.15, meaning that its stock price is 115% more volatile than the S&P 500.

Valuation and Earnings

This table compares Ascendis Pharma A/S and Kura Oncology's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ascendis Pharma A/S$14.98 million441.02$-244,180,000.00($5.25)-23.41
Kura OncologyN/AN/A$-63,140,000.00($1.51)-19.10

Kura Oncology has lower revenue, but higher earnings than Ascendis Pharma A/S. Ascendis Pharma A/S is trading at a lower price-to-earnings ratio than Kura Oncology, indicating that it is currently the more affordable of the two stocks.

Summary

Kura Oncology beats Ascendis Pharma A/S on 7 of the 13 factors compared between the two stocks.

Kura Oncology (NASDAQ:KURA) and TG Therapeutics (NASDAQ:TGTX) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, earnings, valuation and risk.

Insider and Institutional Ownership

94.7% of Kura Oncology shares are owned by institutional investors. Comparatively, 65.7% of TG Therapeutics shares are owned by institutional investors. 11.0% of Kura Oncology shares are owned by company insiders. Comparatively, 13.2% of TG Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Kura Oncology and TG Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Kura OncologyN/A-30.96%-28.02%
TG Therapeutics-151,798.69%-223.96%-108.08%

Analyst Recommendations

This is a summary of current ratings for Kura Oncology and TG Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Kura Oncology011002.91
TG Therapeutics00503.00

Kura Oncology presently has a consensus target price of $39.5455, suggesting a potential upside of 37.12%. TG Therapeutics has a consensus target price of $64.00, suggesting a potential upside of 39.37%. Given TG Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe TG Therapeutics is more favorable than Kura Oncology.

Volatility and Risk

Kura Oncology has a beta of 2.15, meaning that its share price is 115% more volatile than the S&P 500. Comparatively, TG Therapeutics has a beta of 2.28, meaning that its share price is 128% more volatile than the S&P 500.

Valuation & Earnings

This table compares Kura Oncology and TG Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kura OncologyN/AN/A$-63,140,000.00($1.51)-19.10
TG Therapeutics$150,000.0043,038.06$-172,870,000.00($1.83)-25.09

Kura Oncology has higher earnings, but lower revenue than TG Therapeutics. TG Therapeutics is trading at a lower price-to-earnings ratio than Kura Oncology, indicating that it is currently the more affordable of the two stocks.

Summary

Kura Oncology beats TG Therapeutics on 8 of the 13 factors compared between the two stocks.

Kura Oncology (NASDAQ:KURA) and Ionis Pharmaceuticals (NASDAQ:IONS) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, earnings, valuation and risk.

Insider and Institutional Ownership

94.7% of Kura Oncology shares are owned by institutional investors. Comparatively, 84.1% of Ionis Pharmaceuticals shares are owned by institutional investors. 11.0% of Kura Oncology shares are owned by company insiders. Comparatively, 2.4% of Ionis Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Kura Oncology and Ionis Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Kura OncologyN/A-30.96%-28.02%
Ionis Pharmaceuticals7.82%6.57%3.39%

Analyst Recommendations

This is a summary of current ratings for Kura Oncology and Ionis Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Kura Oncology011002.91
Ionis Pharmaceuticals27602.27

Kura Oncology presently has a consensus target price of $39.5455, suggesting a potential upside of 37.12%. Ionis Pharmaceuticals has a consensus target price of $57.9091, suggesting a potential upside of 41.14%. Given Ionis Pharmaceuticals' higher possible upside, analysts clearly believe Ionis Pharmaceuticals is more favorable than Kura Oncology.

Volatility and Risk

Kura Oncology has a beta of 2.15, meaning that its share price is 115% more volatile than the S&P 500. Comparatively, Ionis Pharmaceuticals has a beta of 1.42, meaning that its share price is 42% more volatile than the S&P 500.

Valuation & Earnings

This table compares Kura Oncology and Ionis Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kura OncologyN/AN/A$-63,140,000.00($1.51)-19.10
Ionis Pharmaceuticals$1.12 billion5.12$303.26 million$2.0819.61

Ionis Pharmaceuticals has higher revenue and earnings than Kura Oncology. Kura Oncology is trading at a lower price-to-earnings ratio than Ionis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Ionis Pharmaceuticals beats Kura Oncology on 8 of the 13 factors compared between the two stocks.


Kura Oncology Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Ultragenyx Pharmaceutical logo
RARE
Ultragenyx Pharmaceutical
1.4$108.72-0.8%$7.28 billion$103.71 million-24.77Analyst Revision
Arrowhead Pharmaceuticals logo
ARWR
Arrowhead Pharmaceuticals
1.5$67.56-0.6%$7.06 billion$87.99 million-80.43News Coverage
GW Pharmaceuticals logo
GWPH
GW Pharmaceuticals
1.5$218.90-0.0%$6.86 billion$311.33 million-127.27Increase in Short Interest
Ascendis Pharma A/S logo
ASND
Ascendis Pharma A/S
1.5$122.91-1.0%$6.67 billion$14.98 million-14.97Analyst Downgrade
TG Therapeutics logo
TGTX
TG Therapeutics
1.8$45.92-0.2%$6.44 billion$150,000.00-21.66Unusual Options Activity
News Coverage
Gap Down
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.6$40.78-0.6%$5.74 billion$1.12 billion84.96
Allakos logo
ALLK
Allakos
1.7$105.33-2.7%$5.74 billionN/A-38.44Insider Selling
Sarepta Therapeutics logo
SRPT
Sarepta Therapeutics
1.9$71.80-1.2%$5.70 billion$380.83 million-9.18Analyst Report
Perrigo logo
PRGO
Perrigo
2.5$41.62-1.1%$5.56 billion$4.84 billion-693.55
Blueprint Medicines logo
BPMC
Blueprint Medicines
1.5$95.20-0.8%$5.52 billion$66.51 million17.56Analyst Report
Analyst Revision
Schrödinger logo
SDGR
Schrödinger
1.3$78.18-0.2%$5.49 billion$85.54 million0.00Insider Selling
News Coverage
Galapagos logo
GLPG
Galapagos
1.3$79.15-0.3%$5.19 billion$1.00 billion-11.99Analyst Upgrade
Biohaven Pharmaceutical logo
BHVN
Biohaven Pharmaceutical
2.0$74.56-1.7%$4.70 billionN/A-6.08Analyst Revision
Sage Therapeutics logo
SAGE
Sage Therapeutics
1.4$76.13-0.8%$4.41 billion$6.87 million-7.36Unusual Options Activity
Analyst Revision
Hutchison China MediTech logo
HCM
Hutchison China MediTech
1.4$29.25-0.4%$4.26 billion$204.89 million-36.56
Emergent BioSolutions logo
EBS
Emergent BioSolutions
2.0$77.64-4.1%$4.16 billion$1.11 billion24.96Analyst Report
I-Mab logo
IMAB
I-Mab
1.2$57.00-0.2%$4.11 billion$4.31 million-1.97Increase in Short Interest
Gap Up
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.7$65.90-3.2%$3.98 billion$806.43 million-9.33Analyst Report
Agios Pharmaceuticals logo
AGIO
Agios Pharmaceuticals
1.3$54.28-1.4%$3.84 billion$117.91 million-11.01
Atea Pharmaceuticals logo
AVIR
Atea Pharmaceuticals
2.0$44.83-2.6%$3.81 billionN/A0.00Analyst Report
Increase in Short Interest
Apellis Pharmaceuticals logo
APLS
Apellis Pharmaceuticals
1.6$45.57-1.8%$3.66 billionN/A-6.14Analyst Report
Analyst Revision
News Coverage
Gap Down
Turning Point Therapeutics logo
TPTX
Turning Point Therapeutics
1.7$73.03-5.8%$3.58 billionN/A-20.81Analyst Report
Insmed logo
INSM
Insmed
1.2$32.62-3.1%$3.47 billion$136.47 million-12.55
Nektar Therapeutics logo
NKTR
Nektar Therapeutics
1.5$19.00-1.9%$3.46 billion$114.62 million-7.66Analyst Report
LEGN
Legend Biotech
1.2$26.00-0.8%$3.46 billion$64.39 million0.00Decrease in Short Interest
Gap Down
ACADIA Pharmaceuticals logo
ACAD
ACADIA Pharmaceuticals
1.9$21.14-0.3%$3.39 billion$339.08 million-12.29Analyst Report
PTC Therapeutics logo
PTCT
PTC Therapeutics
1.3$48.96-1.6%$3.39 billion$306.98 million-7.00
Reata Pharmaceuticals logo
RETA
Reata Pharmaceuticals
1.4$90.87-1.5%$3.29 billion$26.52 million-8.01
ChemoCentryx logo
CCXI
ChemoCentryx
1.6$47.37-0.5%$3.29 billion$36.13 million-70.70
Arvinas logo
ARVN
Arvinas
1.5$64.69-2.6%$3.16 billion$42.98 million-25.27
Alkermes logo
ALKS
Alkermes
1.2$19.65-0.6%$3.15 billion$1.17 billion-42.72
MorphoSys logo
MOR
MorphoSys
0.3$22.75-1.9%$3.05 billion$80.43 million108.34Decrease in Short Interest
Karuna Therapeutics logo
KRTX
Karuna Therapeutics
1.8$112.60-4.2%$3.04 billionN/A-56.02Insider Selling
Pacira BioSciences logo
PCRX
Pacira BioSciences
2.1$62.88-5.5%$2.91 billion$421.03 million22.14Analyst Report
Insider Selling
News Coverage
Gap Up
OPKO Health logo
OPK
OPKO Health
1.9$4.34-0.5%$2.91 billion$901.90 million-24.11
Taro Pharmaceutical Industries logo
TARO
Taro Pharmaceutical Industries
0.9$75.64-1.6%$2.89 billion$644.77 million-10.79
Organogenesis logo
ORGO
Organogenesis
1.0$21.22-6.5%$2.89 billion$260.98 million-353.67
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.6$10.10-2.3%$2.73 billion$182.24 million-8.78Analyst Upgrade
Deciphera Pharmaceuticals logo
DCPH
Deciphera Pharmaceuticals
1.6$45.18-4.5%$2.72 billion$25 million-9.04Insider Selling
Rocket Pharmaceuticals logo
RCKT
Rocket Pharmaceuticals
1.4$43.67-0.3%$2.71 billionN/A-23.99
Corcept Therapeutics logo
CORT
Corcept Therapeutics
1.5$22.77-0.7%$2.67 billion$306.49 million25.58
Intra-Cellular Therapies logo
ITCI
Intra-Cellular Therapies
1.7$31.28-3.4%$2.62 billion$60,000.00-9.71
Xencor logo
XNCR
Xencor
1.2$42.78-4.4%$2.59 billion$156.70 million-30.56
Global Blood Therapeutics logo
GBT
Global Blood Therapeutics
1.4$40.88-1.1%$2.57 billion$2.11 million-8.85Analyst Report
Analyst Revision
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.6$150.23-0.9%$2.50 billion$120.28 million-151.75Analyst Report
Decrease in Short Interest
Arcus Biosciences logo
RCUS
Arcus Biosciences
2.0$33.76-3.6%$2.48 billion$15 million-17.68Unusual Options Activity
ALX Oncology logo
ALXO
ALX Oncology
1.9$60.50-0.2%$2.42 billionN/A0.00Analyst Report
Insider Selling
Increase in Short Interest
Cryoport logo
CYRX
Cryoport
1.9$51.57-2.6%$2.35 billion$33.94 million-88.91Gap Up
Prestige Consumer Healthcare logo
PBH
Prestige Consumer Healthcare
1.6$45.22-0.4%$2.25 billion$963.01 million14.04
Dicerna Pharmaceuticals logo
DRNA
Dicerna Pharmaceuticals
2.0$29.33-2.7%$2.18 billion$23.90 million-18.22Analyst Report
Unusual Options Activity
Gap Down
This page was last updated on 4/16/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.